May 01, 2017 8:00am EDT AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
Dec 15, 2016 5:15pm EST AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
Sep 22, 2016 8:00am EDT AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
Jun 22, 2016 8:00am EDT AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
Jan 06, 2016 8:30am EST AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
Nov 17, 2015 8:30am EST AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
Sep 16, 2015 7:30am EDT AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
